Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Anorexia nervosa causes gastroparesis, constipation, and can lead to elevated liver enzymes. It is often necessary to supplement the diet of patients with nutritional formulas. The ingestion of a peptide formula, with partially hydrolyzed protein and rich in medium chain triglycerides, could favor its digestion and absorption, improving its tolerance and acceptance by the patient, compared to a polymeric formula.
Main objective:
• To compare the digestive tolerance of an oligomeric nutritional supplement with respect to a polymeric nutritional supplement in a group of patients diagnosed with anorexia nervosa under follow-up by the Nutrition Unit.
Secondary Objectives:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Oligomeric nutritional formula arm (Bi1 peptidic) | Experimental | Individuals will receive a Oligomeric nutritional formula. |
|
| Standard arm | Other | Individuals will receive a Standard nutritional formula. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Experimental Treatment, Oligomeric nutritional formula | Other | Intervention group will receive a oligomeric nutritional formula (Bi1 peptidic Adventia Pharma, Spain). |
|
| Measure | Description | Time Frame |
|---|---|---|
| Compare the digestive tolerance of an oligomeric nutritional supplement with respect to a polymeric nutritional supplement in a group of patients diagnosed with anorexia nervosa under follow-up by the Nutrition Unit. | Differences in the score of the questionnaire: "Evaluation questionnaire for gastrointestinal complaints". This questionnaire assesses the presence (and where appropriate its degree) or absence of nausea, vomiting, diarrhea, constipation, reflux or heartburn. Each section has a score from 0 to 10, which will be filled in by the patient himself. | From baseline to week 1 |
| Measure | Description | Time Frame |
|---|---|---|
| Assess the gastrointestinal tolerance of the oral nutritional supplement on a single occasion with respect to a continuous intake over a period of 4 weeks. | Difference in score in the questionnaire "Evaluation questionnaire for gastrointestinal complaints". This questionnaire assesses the presence (and where appropriate its degree) or absence of nausea, vomiting, diarrhea, constipation, reflux or heartburn. Each section has a score from 0 to 10, which will be filled in by the patient himself. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gabriel MD Olveira, PhD | Hospital Regional Universitario de Málaga, FIMABIS | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Regional Universitario de Málaga | Málaga | MALAGA | 29009 | Spain |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40164776 | Derived | Ruiz Garcia I, Porras Perez N, Garcia Torres F, Olivas Delgado L, Sanchez Torralvo FJ, Pascual Lopez M, Fernandez Marzalo C, Olveira G. Comparison of the digestive tolerance of an oligomeric versus a polymeric oral nutritional supplement in people with anorexia nervosa. A randomised crossover clinical trial. Eur J Clin Nutr. 2025 Aug;79(8):780-786. doi: 10.1038/s41430-025-01608-y. Epub 2025 Mar 31. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000856 | Anorexia Nervosa |
| D044342 | Malnutrition |
| D001008 | Anxiety Disorders |
| D003863 | Depression |
| ID | Term |
|---|---|
| D001068 | Feeding and Eating Disorders |
| D001523 | Mental Disorders |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Control Treatment | Other | Standard nutritional formula (isocaloric and isoprotein compared to the experimental treatment). |
|
| From baseline to week 1 in group 1; from baseline to week 8 in group 2 |
| Compare the sensory perception of a polymeric nutritional supplement with respect to an oligomeric one. | Change in the score of the "Product sensory evaluation questionnaire". It consists of 11 items, which assess how the patient perceives the organoleptic characteristics of the product and their satisfaction after taking it. Each item consists of a score from 0 to 10 that the patient has to fill in. The items can refer to positive or negative characteristics of the product, so the level of score in each of them can indicate better or worse characteristics of the product depending on the characteristic in question. | From baseline to week 1 in group 1; from baseline to week 8 in group 2 |
| Compare adherence to treatment in group 2 subjects. | Adherence will be determined by daily registration of the percentage they take of the supplement. | From baseline to week 8 in group 2 |
| Evaluate the intake of natural food in group 2 patients. | Dietary registration of natural food intake at breakfast, mid-morning snack and lunch, in group 2 patients. It will be done through the DIETSTAT program. The total amount of calories and the percentage of macronutrients will be determined. | From baseline to week 8 in group 2 |
| Changes in weight | Weight will be measured in kg | From baseline to week 8 |
| Change in hand grip strength | It will be determined with a JAMAR dynamometer. The mean and maximum of three measurements made on the dominant hand and the mean and maximum of three measurements made on the non-dominant hand will be taken. The outside will be measured in kg. | From baselilne to week 8 |
| Change in fat mass | Determined by AKERN bioimpedance analyzer and measured in kg | From baselilne to week 8 |
| Change in lean mass | Determined by AKERN bioimpedance meter and measured in kg | From baselilne to week 8 |
| Change in extracellular water | Determined by AKERN bioimpedance analyzer and measured in l | From baselilne to week 8 |
| Change in intracellular water | Determined by AKERN bioimpedance analyzer and measured in l | From baselilne to week 8 |
| Change in phase angle | Determined by AKERN bioimpedance analyzer and measured in degrees of angle | From baselilne to week 8 |
| Change in total cell mass | Determined by AKERN bioimpedance analyzer and measured in kg | From baselilne to week 8 |
| Evaluate the impact of oral nutritional supplementation on the quality of life of the patient | Changes in the score of the "SF-12 Health Questionnaire" questionnaire. This questionnaire is the adaptation made for Spain of the SF-12 Health Survey. The SF-12 is a shortened version of the SF-36 Health Questionnaire designed for uses where it is too long. Provides a health status profile. It consists of 12 items from the 8 dimensions of the SF-36 Physical Function (2), Social Function (1), Physical role (2), Emotional role (2), Mental health (2), Vitality (1), Body pain (1), General Health (1). The response options form Likert-type scales that assess intensity or frequency. The number of answer options ranges from three to six, depending on the item. For each of the 8 dimensions, the items are coded, added and transformed on a scale that ranges from 0 (the worst health status for that dimension) to 100 (the best health status). | From baselilne to week 8 |
| Changes in eating habits and styles | Changes in the score of the "Eating Disorder Examination-Q (EDE-Q)" test. This questionnaire takes about 10 minutes to complete. It studies the scope and severity of the characteristics associated with the diagnosis of eating disorder. It includes 4 subscales: Restriction-diet, Preoccupation with food, Preoccupation with weight and Concern about the figure. Includes a definition of the term "binge" (eg, "episodes in which you have eaten an abnormally large amount of food under the circumstances" and experiencing a "loss of control" over eating). The EDE-Q generates two types of data: frequency data on key behavioral features of eating disorders in terms of number of episodes of the behavior, and subscale scores reflecting the severity of characteristics of eating disorders. Higher scores on the global scale and subscales denote more problematic eating behaviors and attitudes. | From baselilne to week 8 |
| Assess the impact of oral nutritional supplementation on the patient's depressive and anxious symptoms. | Changes in the score of the "Hospital Anxiety and Depression Scale (HADS)". This aims to detect depressive and anxiety disorders in non-psychiatric hospital services, avoiding overlap with symptoms due to physical illness, without taking into account the physical aspects that may accompany anxiety / depression, only affecting the emotional ones. It is a self-administered scale with 14 items divided into 2 subscales (anxiety and depression) whose maximum score is 21 points for each of them. Based on the score obtained, patients can be classified as normal (<7), doubtful (between 8 and 10) and potential clinical case (≥ 11). The score is referred to the last week. | From baseline to week 8 |
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |